Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BGP-15 (BGP-15 2HCl) is a PARP inhibitor with protecting effect after ischemia-reperfusion injury.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 38.00 | |
5 mg | In stock | $ 61.00 | |
10 mg | In stock | $ 101.00 | |
25 mg | In stock | $ 198.00 | |
50 mg | In stock | $ 369.00 | |
100 mg | In stock | $ 479.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 66.00 |
Description | BGP-15 (BGP-15 2HCl) is a PARP inhibitor with protecting effect after ischemia-reperfusion injury. |
Targets&IC50 | PARP:120 μM |
In vitro | In two mouse models developed to exhibit heart failure and atrial fibrillation, BGP-15 has been shown to enhance cardiac function and reduce arrhythmia [2]. Pretreatment with BGP-15 (100-200 mg/kg, p.o.) before cisplatin administration can either prevent or significantly inhibit the development of cisplatin-induced acute renal failure. BGP-15 demonstrates significant antioxidant effects on the kidneys in the context of cisplatin-induced nephrotoxicity. Despite BGP-15's ability to protect the kidneys from nephrotoxic effects, it does not diminish the antitumor efficacy of cytostatic agents. In the kidneys, BGP-15 inhibits cisplatin-induced poly(ADP-ribose) polymerization [1]. |
In vivo | BGP-15 acts as an in vitro inducer of HSP72, effective only when co-treated with heat shock, without affecting HSP90 levels. At a concentration of 200 μM, BGP-15 mitigates the depletion of high-energy phosphate compounds and prevents oxidative damage induced by imatinib mesylate. This is achieved by promoting the phosphorylation of Akt and GSK-3beta, and inhibiting the activation of p38 MAPK and JNK, thereby altering the signaling effects of imatinib mesylate. Moreover, BGP-15 significantly inhibits the activation of p38 and JNK, enzymes known to facilitate cell death and inflammatory responses in ex vivo perfused hearts. |
Cell Research | Human tumor cell lines A549, HCT-15, HCT-116, and Du-145 were maintained in RPMI 1640 medium supplemented with 10% FCS in humidified air containing 5% CO2. For in vitro cytotoxicity assays, 5×103 to 5×104 cells were plated into the wells of 96-well plates in 100 μL culture medium. On the following day, cells were exposed to BGP-15 (10, 30, 100 μg/mL) and to a series of concentrations of cisplatin either by itself or in combination. Cultures were incubated in a total volume of 200 μL for 3 more days at 37°. Samples were prepared in duplicates or triplicates. Cell growth was evaluated by MTT or SRB assays. Growth inhibition curves were calculated. (Only for Reference) |
Synonyms | BGP15, BGP-15 2HCl |
Molecular Weight | 351.27 |
Formula | C14H24Cl2N4O2 |
CAS No. | 66611-37-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 64 mg/mL (182.2 mM)
Ethanol: 65 mg/mL (185 mM)
DMSO: 65 mg/mL (185 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BGP-15 66611-37-8 Chromatin/Epigenetic DNA Damage/DNA Repair PARP inhibit Inhibitor BGP 15 poly ADP ribose polymerase BGP15 BGP-15 2HCl inhibitor